South Asian diabetes patients in UK resist medication: study

Image
Press Trust of India London
Last Updated : Feb 10 2017 | 12:13 PM IST
The social stigma attached with diabetes and the fear of being poisoned by medical drugs is contributing to patients from South Asian background - India, Pakistan or Bangladesh - in the UK failing to take their medication, a new study has found.
For people from South Asian origin, diabetes and insulin were viewed as culturally unacceptable, making some patients reluctant to start insulin therapy or even admit to family and friends that they had the condition, researchers said.
"Not taking medicines - for whatever reason - can have a profound effect on patients' health and poor clinical outcomes for those withdiabetes and cardiovascular disease," said Dr Paramjit Gill, from the University of Birmingham'sInstitute of Applied Health Research.
"We identified a range of beliefs that influence how patients from South Asian communities approach taking medication for these conditions. These patients would benefit from tailored medicaladvice that highlights the long-term consequences of diabetes and CVD," said Gill.
South Asians in Britain are six times more likely than the general population to be affected with diabetes at a younger age and at greater risk of developing cardiovascular complications. Type 2 Diabetes is a major risk factor associated with heart disease.
Scientists recommend that South Asian patients would benefit from health professionals giving them tailored advice that highlights the long-term consequences of diabetes and cardiovascular disease (CVD).
Researchers studied the factors that influenced behaviour around taking medicines and identified a number of key areas that helped to shape when South Asian patients took their medication: Beliefs about the need for medicines and their effectiveness, fears around the toxicity of medicines, traditional remedies versus 'Western' medicines, stigma and social support and communication by health professionals.
"Health beliefs found in South Asian diabetic patients are present in other chronic diseases such as rheumatoid arthritis. These health beliefs should be explored when consulting South Asian patients about using long-term medication," Dr Kanta Kumar, one of the researchers, said.
The study, published in the journal BMC Endocrine Disorders, found that some patients were concerned about increasing numbers of prescribed medicines being added to their treatment plans - compounding their fears about toxicity.
Many patients missed doses intentionally because they
'felt fine' or their symptoms had become less severe. Others decided to stop their treatment during social gatherings - often stopping their medicines to take part fully in activities such as weddings.
The study foundmany patients of South Asian origin regarded medicines for treatment of diabetes and CVD as necessary.
However, patients who had migrated to the UK described the medicines they received in Britain as more effective than those they would have received in places like India and Pakistan.
Some patients used traditional and herbal remedies rather than 'Western' medicines, believing them to better at tackling illnesses without side effects. Family and friends were often important in deciding whether to take these medicines and, in some cases, would also supply them.
Health professionals' communication styles were found to influence the way patients viewed the treatment of their disease. Some patients felt that they were not always fully informed about disease management and how medication would help to control their symptoms.
The findings suggest that if health professionals took patients' beliefs about medicines into account when prescribing, this would help them to better advise diabetes and CVD sufferers about the benefits of taking their medication on a regular basis.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 10 2017 | 12:13 PM IST

Next Story